Myriad Genetics and Personalis Cross-License Foundational MRD Intellectual Property to Broaden Patient Access to Testing
11 juil. 2024 09h00 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY and FREMONT, Calif., July 11, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (Nasdaq: MYGN), a leader in genetic testing and precision medicine, and Personalis, Inc. (Nasdaq: PSNL)...
Burning Rock Reports First Quarter 2024 Financial Results
29 mai 2024 01h34 HE
|
Burning Rock Biotech Limited
Burning Rock Reports First Quarter 2024 Financial Results
International Myeloma Foundation Celebrates ODAC Meeting Outcome on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval of Myeloma Drugs in Clinical Trials: A Huge Win for the Global Myeloma Community
12 avr. 2024 16h08 HE
|
International Myeloma Foundation
International Myeloma Foundation Celebrates ODAC Meeting on Minimal Residual Disease (MRD) Testing as an Early Endpoint for the Accelerated Approval.
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
28 mars 2024 17h16 HE
|
Burning Rock Biotech Limited
Burning Rock Reports Fourth Quarter and Full Year 2023 Financial Results
Myriad Genetics Announces Foundational Patent Granted for Molecular Residual Disease (MRD) with Early Priority Date
21 mars 2024 21h40 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, March 21, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc., (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced that the United States Patent and...
Myriad Genetics and National Cancer Center Hospital East in Japan Collaborate on Pan-Cancer MRD Monitoring Clinical Trial, SCRUM-MONSTAR-SCREEN-3
27 févr. 2024 09h15 HE
|
Myriad Genetics, Inc.
SALT LAKE CITY, Feb. 27, 2024 (GLOBE NEWSWIRE) -- Myriad Genetics, Inc. (NASDAQ: MYGN), a leader in genetic testing and precision medicine, today announced a research collaboration with the National...
Burning Rock Announces Receipt of Notification from NASDAQ
04 janv. 2024 01h03 HE
|
Burning Rock Biotech Limited
Burning Rock Announces Receipt of Notification from NASDAQ
Burning Rock Announces Results of 2023 Annual General Meeting
19 déc. 2023 21h35 HE
|
Burning Rock Biotech Limited
Burning Rock Announces Results of 2023 Annual General Meeting
Adaptive Biotechnologies Announces New Data Highlighting the Clinical Relevance of MRD Testing with clonoSEQ® in Patients with Blood Cancers at the 65th ASH Annual Meeting
09 déc. 2023 08h30 HE
|
Adaptive Biotechnologies
Treatment adapted studies show the potential for MRD assessment to guide the personalization of blood cancer careNew data demonstrates MRD assessed from blood in multiple myeloma may be an indicator...
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023
20 nov. 2023 20h55 HE
|
Burning Rock Biotech Limited
Burning Rock Schedules Third Quarter of 2023 Earnings Release on November 30, 2023